30 June 2026
As a proudly independent HealthScience communications consultancy, Oxford PharmaGenesis has worked tirelessly to earn deep client trust, growing through repeat business and personal recommendation in medical affairs and market access.
14–17 September 2016, London, UK These are exciting times in the field of multiple sclerosis (MS) management; the past 5 years have seen an explosion in the number of disease-modifying therapies (DMTs) licensed for the treatment of patients with relapsing–remitting MS (RRMS).
The 2016 Medical Affairs Strategic Summit (MASS) West began on 14 September in San Diego, California, USA. The 3-day summit hosted professionals involved in all aspects of medical affairs including clinical research, health economics, key opinion leadership, medical communications and publication planning.
Oxford PharmaGenesis insights into patient-reported outcomes (PROs), health literacy and patient-centricity were the subject of the September edition of the International Society for Medical Publication Professionals (ISMPP) online education series, ISMPP University (ISMPP U).
Today, the Right Honourable Edward Vaizey, local MP for Wantage, visited award-winning HealthScience communications consultancy Oxford PharmaGenesis to discuss the implications of Brexit for trade, education, research and health funding in Oxfordshire.
